UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q/A
First Amendment
QUARTERLY
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the Quarter ended June 30, 2021
Commission
File Number: 000-54942
BLUE BIOFUELS, INC.
(Exact
name of small Business Issuer as specified in its charter)
Nevada
45-4944960
(State
or other jurisdiction of
(IRS
Employer
incorporation
or organization)
Identification
No.)
3710 Buckeye Street , Suite 120
Palm Beach Gardens , FL
33410
(Address
of principal executive offices)
(Zip
Code)
Registrant’s
telephone number, including area code: ( 888 ) 607-3555
ALLIANCE
BIOENERGY PLUS, INC.
Former
name or former address if changed since last report
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Not
applicable.
Check
whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes
☒
No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting
company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company”
in Rule 12b-2 of the Exchange Act.
Large
Accelerated Filer ☐
Accelerated
Filer ☐
Non-Accelerated Filer ☐
Emerging
Growth Company ☐
Smaller
reporting company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐ Yes ☒ No
The
number of the registrant’s shares of common stock outstanding were 272,411,065 as of August 12, 2021.
Explanatory Note
The purpose of this Amendment #1 to the Form 10-Q
Quarterly Report filed on August 13, 2021, is to check the yes box for having filed all required reports and having been subject to such
filing requirements for the past 90 days. We were not subject to such filing requirements for 90 days as of the last quarter, but are
now. In all other respects, the Form 10-Q Quarterly Report filed on August 13, 2021 is unchanged.
TABLE
OF CONTENTS
Page
PART I—FINANCIAL INFORMATION
ITEM
1.
Consolidated Financial Statements (unaudited)
4
ITEM
2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
18
ITEM
3.
Quantitative and Qualitative Disclosures About Market Risk
22
ITEM
4.
Controls and Procedures
22
PART II—OTHER INFORMATION
ITEM
1.
Legal Proceedings
24
ITEM
1A.
Risk Factors
24
ITEM
2.
Unregistered Sales of Equity Securities and Use of Proceeds
24
ITEM
3.
Defaults Upon Senior Securities
26
ITEM
4.
Mine Safety Disclosures
26
ITEM
5.
Other Information
26
ITEM
6.
Exhibits
27
Signatures
28
2
PART
I – FINANCIAL INFORMATION
TABLE
OF CONTENTS
Index
to Financial Statements
Page
Condensed Consolidated Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020
4
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020 (unaudited)
5
Condensed Consolidated Statements of Stockholders’ Equity for the Six Months Ended June 30, 2021 and 2020 (unaudited)
6
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (unaudited )
7
Notes to Condensed Consolidated Financial Statements (unaudited)
8
3
Blue
Biofuels, Inc.
Formerly known as Alliance Bioenergy Plus, Inc.
Financial
Statements
Period
Ended June 30, 2021
UNAUDITED
FINANCIAL STATEMENTS
OF
BLUE
BIOFUELS, INC.
Blue
Biofuels, Inc.
Formerly
known as Alliance Bioenergy Plus, Inc.
CONSOLIDATED
BALANCE SHEETS
(unaudited)
June 30, 2021
December 31, 2020
ASSETS
Current assets
Cash and cash equivalents
$ 1,863,097
$ 286,579
Prepaid expenses
78,415
45,324
TOTAL CURRENT ASSETS
$ 1,941,512
$ 331,903
Other assets
Property and equipment, net of accumulated depreciation and amortization of $ 250,051
and $ 231,739 at June 30, 2021 and December 31,2020, respectively
305,131
247,431
Security deposits
30,276
30,276
Right of Use Assets, net of accumulated amortization
105,364
144,876
Patents
152,520
138,016
TOTAL OTHER ASSETS
$ 593,291
$ 560,599
TOTAL ASSETS
$ 2,534,803
$ 892,502
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable
$ 22,879
$ 90,965
Accounts payable - Related Party
76,670
$ 76,670
Deferred wages and director’s fees - Related party
235,795
$ 676,477
Lease Liability - Current
83,825
$ 80,078
Convertible Debentures — Related Party
-
75,000
Interest Payable - Related Party
56,868
99,268
TOTAL CURRENT LIABILITIES
$ 476,037
$ 1,098,458
Long term liabilities
Right of Use Lease Liability, net of current portion
29,372
72,346
Paycheck Protection Program SBA loan
-
66,330
Chapter 11 Settlement
50,000
50,000
Notes Payable — Related Party
2,521,562
2,521,562
Notes Payable — Other
216,570
216,570
Convertible debenture, payable from future profits —
Related Party
-
204,000
TOTAL LONG TERM LIABILITIES
$ 2,817,504
$ 3,130,808
TOTAL LIABILITIES
$ 3,293,541
$ 4,229,266
STOCKHOLDERS’ EQUITY (deficit)
Preferred stock; $ 0.001 par value; 10,000,000 shares authorized; zero shares
issued and outstanding
-
-
Common stock; $ 0.001 par value; 1,000,000,000 shares authorized; 272,311,065
issued and outstanding at June 30, 2021, and 241,721,947 shares issued and outstanding at December 31, 2020.
272,311
241,722
Additional paid-in capital
46,750,163
43,103,607
Accumulated deficit
( 47,781,212 )
( 46,682,093 )
Total stockholders’ equity
$ ( 758,738 )
$ ( 3,336,764 )
TOTAL EQUITY (DEFICIT)
$ ( 758,738 )
$ ( 3,336,764 )
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
$ 2,534,804
$ 892,502
4
Blue
Biofuels, Inc
Formerly
known as Alliance Bioenergy Plus, Inc.
CONSOLIDATED
STATEMENT OF OPERATIONS
(unaudited)
Three Months Ended
Six Months Ended
30-Jun
30-Jun
2021
2020
2021
2020
Revenues
$ -
$ -
$ -
$ -
Operating expense:
General and administrative
293,372
678,106
599,649
878,140
Research & Development
249,786
492,117
514,860
582,733
Loss on disposal of assets
-
-
33,484
-
Total operating expenses
543,158
1,170,223
1,147,992
1,460,873
Loss from operations:
( 543,158 )
( 1,170,223 )
( 1,147,992 )
( 1,460,873 )
Other (income) expense:
Loan Forgiveness
( 66,330 )
-
( 66,330 )
-
Interest expense - related party
6,812
34,197
13,661
139,275
Interest expense - other
1,896
1,840
3,796
3,966
Total other (income) expense
( 57,622 )
36,037
( 48,873 )
143,241
Income (Loss) before provisions for income taxes
$ ( 485,535 )
$ ( 1,206,260 )
$ ( 1,099,119 )
$ ( 1,604,114 )
Provisions for income taxes
-
-
Net Income / (Loss):
$ ( 485,535 )
$ ( 1,206,260 )
$ ( 1,099,119 )
$ ( 1,604,114 )
Net income (loss) per share
$ ( 0.002 )
$ ( 0.005 )
$ ( 0.004 )
$ ( 0.007 )
Weighted average common shares outstanding
Basic
266,513,255
224,059,843
266,513,255
224,059,843
5
Blue
Biofuels, Inc.
Formerly
known as Alliance Bioenergy Plus, Inc.
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
Common Stock
Preferred Stock
Additional Paid-in
Accumulated
Total Stockholder’s
Shares
Amount
Shares
Amt
Capital
Deficit
(Deficit)
Balance as of December 31, 2019
219,513,233
$ 219,513
-
-
$ 40,949,645
$ ( 44,500,966 )
$ ( 3,331,808 )
Issuance of common stock for services
705,352
705
-
-
34,295
-
35,000
Issuance of warrants for services
Warrants exercised
Warrants exercised, shares
Issuance of common stock and warrants for cash through PPM
9,025,129
9,025
-
-
538,355
-
547,380
Issuance of common stock in exchange for debt
Issuance of common stock in exchange for debt, shares
Issuance of 10,300,000 vested options under the employee, director plan
-
-
847,574
-
847,574
Employee stock options exercised
Employee stock options exercised, shares
Cashless exercise of stock options
Cashless exercise of stock options, shares
Net Income (Loss)
( 1,604,114 )
$ ( 1,604,114 )
Balance as of June 30, 2020
229,243,714
$ 229,243
-
-
$ 42,369,869
$ ( 46,105,080 )
$ ( 3,505,968 )
Balance as of December 31, 2020
241,721,947
$ 241,722
-
-
$ 43,103,607
$ ( 46,682,093 )
$ ( 3,336,764 )
Issuance of common stock for services
223,000
$ 223
-
-
$ 46,707
-
$ 46,930
Issuance of 1,166,667 warrants for services
-
-
-
72,090
-
72,090
Issuance of warrants for services
-
-
-
72,090
-
72,090
Warrants exercised
13,455,009
13,455
-
-
1,289,362
-
1,302,817
Issuance of common stock and warrants for cash through PPM
9,303,331
9,303
-
-
1,941,447
-
1,950,750
Issuance of common stock in exchange for debt
7,080,000
7,080
-
-
271,920
-
279,000
Issuance of 210,000 vested options under the employee, director plan
-
12,658
12,658
Issuance of vested options under the employee, director plan
-
12,658
12,658
Employee stock options exercised
350,000
350
-
-
12,550
-
12,900
Cashless exercise of stock options
177,778
178
-
-
( 178 )
-
( 0 )
Net Income (Loss)
( 1,099,119 )
$ ( 1,099,119 )
Balance as of June 30, 2021
272,311,065
$ 272,311
-
-
$ 46,750,163
$ ( 47,781,212 )
$ ( 758,738 )
6
Blue
Biofuels, Inc.
Formerly
known as Alliance Bioenergy Plus, Inc.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(Unaudited)
For the Six Months Ended
For the Six Months Ended
30-Jun-21
30-Jun-20
Cash flows from operating activities
Net Income (Loss)
$ ( 1,099,119 )
$ ( 1,604,114 )
Reconciliation of net loss to net cash used in operating activities
Depreciation and amortization
63,001
59,271
Stock based compensation for services
46,930
35,000
Net Issuance of options and warrants for services
84,748
847,574
Loss on Disposal of assets
33,484
-
Changes in operating assets and liabilities
Prepaid expenses
( 33,091 )
63,618
Accrued interest - related party
( 42,400 )
139,275
Accounts payable and accrued liabilities
( 508,768 )
84,711
Forgiveness of PPP Loan
( 66,330 )
-
Right of use lease
( 39,227 )
( 38,084 )
Net cash used in operating activities
( 1,560,772 )
( 412,748 )
Cash flows from investing activities
Purchase of property and equipment
( 114,673 )
( 134,718 )
Security deposits
-
-
Patent Costs
( 14,504 )
( 1,100 )
Net cash from (used in) investing activities
( 129,177 )
( 135,818 )
Cash flows from financing activities
Proceeds from PPP Loan
-
66,330
Proceeds from exercise of warrants and options
1,315,717
-
Net proceeds from issuance of common stock
1,950,750
547,380
Net cash provided by financing activities
3,266,467
613,710
Net increase (decrease) in cash and cash equivalents
1,576,518
65,144
Cash and cash equivalent at beginning of the period
286,579
110,630
Cash and cash equivalent at end of the period
$ 1,863,097
$ 175,774
Supplemental disclosure of cash flow information
Cash paid during the period for
Interest
$ -
$ -
Taxes
$ -
$ -
Supplemental schedule of non-cash activities
Cashless conversion of warrants/options
$ -
$ -
Conversion of convertible debenture to common stock
$ 279,000
$ -
7
Blue
Biofuels, Inc.
Formerly known as Alliance Bioenergy Plus, Inc.
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE
1 – ORGANIZATION
Blue
Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in the renewable energy, biofuels,
and new technologies sectors. In early 2018, our chief executive officer Ben Slager invented a new technology system it calls Cellulose-to-Sugar
2.0 or CTS 2.0, and a patent was granted in April 2021. Three additional patents pertaining to the technology have been filed in 2021.
The 100 % owned CTS 2.0 is a mechanical/chemical dry process for converting cellulose material into sugar for use in the biofuels industry.
CTS 2.0 can convert any cellulosic material – like grasses, wood, paper, farm waste, yard waste, forestry products, energy crops
like hemp, and the cellulosic portion of municipal solid waste – into sugars and lignin, and subsequently into biofuels and bioplastics.
The CTS 2.0 system produces sugar and chemically unmodified sulfur-free lignin among other by-products. The sugar can then be further
converted into biofuels and the lignin into bioplastics.
The
new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter
11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September
18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.
The
Company’s focus is to commercialize its wholly owned CTS 2.0 technology. The Company is currently working with its 4 th generation
prototype and anticipates having a 5 th generation semi-commercial scale system by the beginning of 2022.
Plan
of Operation
The
Company is now doing the engineering work to commercialize its 100% owned CTS 2.0 technology.
The
Company has a strategy to diversify its product portfolio to potentially include the following:
1)
Producing
and selling sugar or ethanol either direct or in combination with joint ventures, mergers, and/or acquisitions of existing businesses
in the renewable energy space;
2)
Producing
and selling low-cost high purity lignin, or using that lignin to produce biodegradable bioplastics, or making biodegradable bioplastics
products and selling them under our own brand.
3)
Producing
and selling other co-products like nanocellulose and specialty chemicals.
NOTE
2 – GOING CONCERN
The
accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which
contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities
in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since
inception. As of June 30, 2021, the Company has a working capital surplus of $ 1,465,475 . As of June 30, 2021, the Company has incurred
accumulated losses of $ 47,781,212 . On October 22, 2018, the Company filed for Chapter 11 bankruptcy. On September 18, 2019, the judge
confirmed the Company’s Chapter 11 Plan, and on October 25, 2019, the bankruptcy case was closed. The Company expects to incur
significant additional losses and liabilities in connection with its start-up and commercialization activities. The Company’s ability
to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its
liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors,
among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do
not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications
of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.
8
Management
believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating
activities and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations,
sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material
adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements
do not include any adjustments that might result from the outcome of this uncertainty.
The
Company intends to raise additional capital and continue engineering work and scaling up towards a full-scale commercial size CTS 2.0
modular unit. At that point, and to minimize dilution to shareholders, the Company will seek project-based financing to build (or acquire
and retrofit) or joint venture with existing ethanol producers to produce cellulosic ethanol and lignin/bioplastics from its patented
CTS 2.0 system. Once the first plant is profitable, the Company intends to grow with additional plants both in the United States and
internationally.
Currently,
the US government gives a D3 RIN to incentivize the production of renewable fuels from cellulosic materials. The value of the D3 RIN
fluctuates, but as of this filing, it is around $3.06 per gallon of ethanol on top of the market price of ethanol.
The
Company believes that its CTS 2.0 process can produce ethanol profitably at the market price, and with the D3 RIN should generate substantial
profits and cash flow in amounts sufficient to cover the Company’s operating expenses and debt service.
Our
business, results of operations, and financial condition may be adversely impacted by the COVID-19 pandemic .
The
COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel
and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption
of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how
it will impact our customers, employees and supply chain. Given the critical nature of the products that we provide, our office and lab
have remained open during the pandemic. The extent to which our operations may be impacted by the COVID-19 pandemic will depend largely
on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due
to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies,
capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may
experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the impacts
of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain
unknown.
NOTE
3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation
The
accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles
in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned
subsidiaries over which the Company exercises control.
Principles
of Consolidation
The
accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany
accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant
influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and
balances were eliminated in consolidation.
Use
of Estimates
The
preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant
estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment
of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations
reasonable under the circumstances. Actual results may differ from these estimates.
9
Cash
and Cash Equivalents
All
highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.
Stock
Compensation
The
Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include
any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient
the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards
made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic
718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers
and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees”
or other applicable authoritative guidance.
Stock-based
Compensation Valuation Methodology
Stock-based
compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance,
the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants
granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants
granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line
basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair
value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the
fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments,
using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market
price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected
term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily
Yield Curve Rate.
The
stock compensation issued for services during the 6 months ended June 30, 2021, was valued on the date of issuance. The following assumptions
were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the six months ended
June 30, 2021:
SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION
1/5/21
5/18/21
Risk-free interest rate
0.96 %
1.64 %
Expected life
10 years
5 years
Expected dividends
0 %
0 %
Expected volatility
209.98 %
176.37 %
ALLM common stock fair value
$ 0.124
$ 0.300
Property
and Equipment
Property
and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful
lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are
expensed as incurred.
Patent
Capitalization
If
a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent
applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the
asset. Conversely, if a product is approved for market (as is the case of the end product ethanol), or if future economic benefit is
probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the
expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use,
the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $ 152,520
as of June 30, 2021 and $ 138,016 as of December 31, 2020.
Research
and Development
The
Company expenses all research and development costs as incurred. For the six months ended June 30, 2021, and June 30, 2020, the amounts
charged to research and development expenses were $ 514,860 , and $ 582,733 , respectively.
10
Revenue
Recognition
The
Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned.
The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However,
no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all
of the following criteria are met:
1.
persuasive
evidence of an arrangement exists;
2.
the
product has been shipped or the services have been rendered to the customer;
3.
the
sales price is fixed or determinable; and,
4.
collectability
is reasonably assured.
Common
Stock Purchase Warrants and Other Derivative Financial Instruments
The
Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash
settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts
are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies
as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an
event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement
in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants
and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities
is required.
Non-controlling
interest in consolidated subsidiaries
The
accompanying consolidated financial statements include the accounts of Blue Biofuels, Inc. and those subsidiaries that the Company has
the ability to control either through voting rights or means other than voting rights. For these subsidiaries, the Company records 100 %
of the revenues, expenses, cash flows, assets and liabilities in its consolidated financial statements. For subsidiaries that the Company
controls but hold less than 100% ownership , a non-controlling interest is recorded in the consolidated income statement to reflect the
non-controlling interest’s share of the net income (loss), and a non-controlling interest is recorded in the consolidated balance
sheet to reflect the non-controlling interest’s share of the net assets of the subsidiary.
Investments
in non-consolidated affiliates
Investments
in non-consolidated affiliates are accounted for using the equity method or cost basis depending upon the level of ownership and/or the
Company’s ability to exercise significant influence over the operating and financial policies of the investee. When the equity
method is used, investments are recorded at original cost and adjusted periodically to recognize the Company’s proportionate share
of the investees’ net income or losses after the date of investment. When net losses from an investment are accounted for under
the equity method exceed its carrying amount, the investment balance is reduced to zero and additional losses are not provided for. The
Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company’s
share of that net income exceeds the share of net losses not recognized during the period the equity method was suspended. Investments
are written down only when there is clear evidence that a decline in value that is other than temporary has occurred.
Impairment
of Long-Lived Assets
Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected
to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying
value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value
of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.
11
Income
Taxes
The
Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.”
Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii)
deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements
or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance
is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is
more likely than not some portion or all of the deferred tax assets will not be realized.
ASC
Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and
prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position
taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties,
accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting
periods presented.
Profit
(Loss) per Common Share:
Basic
profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting
period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect
of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury
stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss
per share amounts are the same as the impact of potential common shares is antidilutive.
Fair
Value Measurements
The
Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used
in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.
The
estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried
at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.
ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
Level
1 — quoted prices in active markets for identical assets or liabilities
Level
2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level
3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
Recent
Accounting Pronouncements
From
time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that
may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements
and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting
or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.
12
NOTE
4 – ASSETS
Patents
The
Company has been granted one patent on its technology, has filed for three others that are pending, and has also applied for international
patents. The Company has capitalized the legal and filing fees in the amount of $ 152,520 as of June 30, 2021.
NOTE
5 – DEBT
Paycheck
Protection Program SBA Loan
In
May 2020, the Company received a loan in the amount of $66,330 under the Payroll Protection Program (“PPP Loan”). The loan
accrues interest at a rate of 1% and has an original maturity date of two years which can be extended to five years by mutual agreement
of the Company and SBA. The PPP loan contains customary events of default relating to, among other things, payment defaults and breaches
of representations and warranties.
Under
the terms of the loan, a portion or all of the loan is forgivable to the extent the loan proceeds are used to fund qualifying payroll,
rent and utilities during a designated twenty-four-week period. Payments are deferred until the SBA determines the amount to be forgiven.
On April 21, 2021, the Company received notice that the entire amount is forgiven.
Notes
Payable – Chapter 11 Settlement
On
July 18, 2018, the Company’s former Controller Dennis Lenaburg sued the Company for $2,694,577 dollars plus stock warrants in the
Circuit Court of the 15 th Judicial Circuit in Palm Beach County, Florida. That lawsuit was moved to the Bankruptcy Court when
the Company entered Chapter 11 on October 22, 2018. The Company filed a Complaint against Lenaburg on November 16, 2018, in the bankruptcy
court in the Southern District of Florida. The bankruptcy judge ordered mediation, and a settlement was reached that paid Lenaburg $13,650
upon Plan Confirmation and a $50,000 claim payable out of post-confirmation net profits over 3 years, plus 1.5 million common stock warrants
with a strike price of $0.30/share and a ten-year expiration period. The $50,000 is due on September 18, 2022.
Notes
Payable – Related Parties
In
July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition
of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per
annum. As of December 31, 2018, and December 31, 2017, the total interest accrued on the notes was $278,794.68 and $176,460 respectively.
All of the notes were due on August 4, 2017 and then were in default. However, the notes were held by related parties with the understanding
that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its
Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving
the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid
from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019.
These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported
quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC,
& Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company,
or, at its option, may convert that into an equity investment in the first plant of the Company, measured by a percentage of the total
cost to build, subject to a minimum equity interest of 1.25% in said plant.
On
February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable
on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These
inducement shares were valued at $84,000 and are being amortized over the life of the note. The note’s maturity date was extended
to 7/1/2018. If the note is not repaid at maturity, then an additional 5,000,000 shares of common stock will be due. The note was renegotiated
during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of
future gross revenues to satisfy this note in full, with no additional shares to be issued.
13
On
May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable
on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well
as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are
being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove
the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter
11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.
On
May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on
May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well
as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are
being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove
the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter
11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.
Notes
Payable – Other
In
July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining
49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As
of December 31, 2018, and December 31, 2017, the total interest accrued on the note was $14,382.2 and $8,588 respectively. The note was
due on August 4, 2017 and was then in default. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan
Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes
mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.
In
November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable
on May 30, 2018. The note carries an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to
the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition,
the Company provided 500,000 inducement shares to secure the note, and may have to provide additional shares on the note’s 6-month
anniversary if the Company’s share price declines. These inducement shares were valued at $39,500 and were amortized over the life
of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment
penalty of the then outstanding principal and interest due. In May 2018, the company made two principal payments totaling $40,000. The
note went into default on June 1, 2018 and incurred a 40% penalty of the outstanding balance immediately prior to the default event.
On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case
was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of
Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation
Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company.
In
February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable
on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount
to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In
addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500, and were
amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the
note will incur a 120% prepayment penalty of the then outstanding principal and interest due. The Note went into default on June 1, 2018,
through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior
to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central
District. That case was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the
Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part
of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to
settle both notes.
On
March 27, 2019, the Company entered into an agreement with Partiz and Company, P.A. such that its debt will be reduced from $32,000 to
$20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization.
The Plan was confirmed by the Court on September 18, 2019.
14
A
summary of all debts indicated in the Notes above is as follows:
SCHEDULE OF NOTES PAYABLE
Notes Payable
June 30, 2021
December 31, 2020
Short Term Convertible Debentures Related Party
$ -
$ 75,000
Long Term Chapter 11 Settlement
$ 50,000
$ 50,000
Long Term Paycheck Protection Program SBA loan
$ -
$ 66,330
Long Term Notes Payable from future revenue — Related Party
$ 1,700,630
$ 1,700,630
Long Term Notes Payable from future revenue — Other
$ 120,000
$ 120,000
Long Term Note Payable from future profits — Related Party
$ 820,932
$ 820,932
Long Term Note Payable from future profits — Other
$ 96,570
$ 96,570
Long Term Convertible Debentures — Related Party
$ -
$ 204,000
TOTAL NOTES
$ 2,788,132
$ 3,133,462
Of
the $2,788,132 due as of June 30, 2021, $2,738,132 is due out of future revenue or future profits. $2,417,502 of the $2,788,132 will
be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would
not be discharged or forgiven is $370,630, consisting of $200,630 due to related parties, $120,000 due to other, and a $50,000 Chapter
11 settlement.
NOTE
6 – STOCKHOLDERS’ EQUITY
The
total number of shares of capital stock, which the Company has authority to issue, is 1,010 million, 1 billion of which are designated
as common stock at $ 0.001 par value (the “Common Stock”) and 10 million of which are designated as preferred stock par value
$ 0.001 (the “Preferred Stock”). As of June 30,2021, the Company had 272,311,065 shares of Common Stock issued and outstanding
and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held
at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative
voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive
any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class,
whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company
has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.
For
the six months ended June 30, 2021, the Company issued an aggregate of 223,000 shares of its common stock for services valued at $ 46,930 .
For
the six months ended June 30, 2021, the Company raised $ 1,950,750 through its private offerings and issued 9,303,331 shares.
For
the six months ended June 30, 2021, 13,455,009 warrants were executed at an average price of $ 0.10 cents/share for total proceeds of
$ 1,302,817 .
For
the six months ended June 30, 2021, the Company issued an aggregate of 1,166,667 warrants for services. Using a Black-Scholes asset-pricing
model, these warrants were valued at $ 72,090 . They have a 6-month term with exercise prices of 15 cents per share.
For
the six months ended June 30, 2021, 200,000 employee stock options were exercised using the cashless exercise provision to obtain 177,778
shares.
For
the six months ended June 30, 2021, 350,000 employee stock options were exercised for proceeds of $ 12,900 .
For
the six months ended June 30, 2021, 13,323,850 warrants expired.
For
the six months ended June 30, 2021, the Company issued 20,730,000 employee stock options, 210,000 of which were vested.
For
the six months ended June 30, 2021, $ 279,000 of convertible notes issued during Chapter 11 converted into 7,080,000 shares of common
stock.
15
NOTE
7 – SEGMENT INFORMATION
The
Company operates in one segment and does not have any revenue to date.
NOTE
8 - COMMITMENTS AND CONTINGENCIES
Litigation
The
Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business.
On
June 21, 2018, Power Up Lending Group Ltd., sued both the Company and four of its managers, ex-managers, and directors of the Company
in the United States District Court for the Eastern District of New York. The case was dropped against the Company and the claim discharged
by the bankruptcy court upon Plan Confirmation on September 18, 2019. Power Up has continued a tort case against the individuals. The
D&O insurance has agreed to cover the CEO Ben Slager, CFO Anthony Santelli, as well as ex-Controller Dennis Lenaburg, in this case.
Management believes the Complaint is frivolous and has filed a motion to dismiss which is pending before the Court as of the date of
this filing.
Leases
The
Company consolidated its premises into one location on November 1, 2019, and currently leases office and laboratory space in Palm Beach
Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s
consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments
over the lease term at the commencement date for leases exceeding 12 months. The lease period is for twenty-four (24) months from November
1, 2019, to October 31, 2021 . This had been extended for one year until October 31, 2022. Annual rent commenced at $ 84,100 per annum
and increases 3 % per year. Tenant is also required to cover operating costs that are estimated at $ 3,084 per month. Operating lease expense
is recognized on a straight-line basis over the lease term and is included in General & Administrative expenses.
ASC
842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not
have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease
liabilities for operating leases.
Rent
expense for the six months ending June 30, 2021, and 2020, were $ 32,384 and $ 31,427 , respectively.
The
Company recognized the following related to leases in its Consolidated Balance Sheet:
SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET
YEAR ENDED
June 30, 2021
December 31, 2020
Right of Use Lease Liabilities
Current portion
83,825
80,078
Long-term portion
29,372
72,346
TOTAL
113,197
152,424
As
of June 30, 2021, the total future minimum lease payments in respect of leased premises are as follows:
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS
YEAR ENDED
MINIMUM DUE
2021
40,852
2022
72,345
2023
0
TOTAL
$ 113,197
16
NOTE
9 – RELATED PARTY TRANSACTIONS
Related
Party Transactions
The
Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related
party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments
in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of
Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees,
such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company;
e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the
management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing
its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting
parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that
one or more of the transacting parties might be prevented from fully pursuing its own separate interests.
1)
Short-term
notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 5.
2)
A
board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben
Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management
to build the Company while they continue to receive less than full salaries.
The
officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business
opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company
and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.
NOTE
10 – SUBSEQUENT EVENTS
The
Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company
has identified the following subsequent events:
From
June 30, 2021, to the date of this filing, the Company raised $ 25,000 in its offering at $ 0.25 /share for 100,000 shares of common stock.
From
June 30, 2021, to the date of this filing, 500,000 warrants expired.
On
July 26, 2021, the Company filed an Amendment to its Articles of Incorporation with the State of Nevada changing the name of the Company
to Blue Biofuels, Inc, and increasing the authorized shares to 1,000,000,000 from 500,000,000 . The Company is waiting for FINRA to approve
the name change and symbol change.
17
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
The
following discussion should be read in conjunction with the Company’s audited financial statements and the notes thereto.
Forward-Looking
Statements
This
quarterly report contains forward-looking statements and information relating to the Company that are based on the beliefs of its management
as well as assumptions made by, and information currently available to, its management. When used in this report, the words “believe,”
“anticipate,” “expect,” “estimate,” “intend”, “plan” and similar expressions,
as they relate to the Company or its management, are intended to identify forward-looking statements. These statements reflect management’s
current view of the Company concerning future events and are subject to certain risks, uncertainties and assumptions, including among
many others: a general economic downturn; a downturn in the securities markets; federal or state laws or regulations having an adverse
effect on proposed transactions that the Company desires to effect; Securities and Exchange Commission regulations which affect trading
in the securities of “penny stocks”; and other risks and uncertainties. Should any of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report as anticipated,
estimated or expected. The accompanying information contained in this registration statement, including, without limitation, the information
set forth under the heading “Management’s Discussion and Analysis and Plan of Operation — Risk Factors” identifies
important additional factors that could materially adversely affect actual results and performance. You are urged to carefully consider
these factors. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the foregoing
cautionary statement.
Business
Overview
Blue
Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in the renewable energy, biofuels,
and bioplastics technologies sectors.
In
early 2018, our chief executive officer Ben Slager invented a new technology system we call Cellulose-to-Sugar or CTS 2.0, and the Company
filed a patent application for this technology. Mr. Slager has since further developed the system with the laboratory personnel. The
CTS 2.0 process is a continuous mechanical/chemical dry process for converting cellulose material into sugar and lignin, as compared
to the CTS 1.0 which is a batch process. The CTS 2.0 creates molecular contact between two reactive solid components instead of a more
conventional reaction which uses liquid or gas components. The reactants are (1) the cellulose, which is broken down into its components
being sugars and lignin; (2) a catalyst, which is cheap and abundantly available, and recycled in the process. The CTS 2.0 machine allows
for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which
optimal efficiency is achieved. The patent on the CTS 2.0 was awarded in 2021 (US10994255). In addition to this patent the Company has
filed three additional patents that are currently pending. The CTS 2.0 technology and related patents represent the results of our continued
development of CTS 2.0 towards commercialization.
CTS
differs from other processes that seek to convert cellulose into sugar. Other processes use enzymes, or expensive chemicals like strong
acids or bases. Some use high temperature or high pressure steam. CTS 2.0 can convert any cellulosic material – including grasses,
wood, paper, farm waste, yard waste, forestry products, energy crops like hemp or king grass, and the cellulosic portion of municipal
solid waste – into sugars and subsequently into biofuels and bioplastics without the use of enzymes or liquid acids. CTS 2.0 has
a near zero carbon footprint, and recycles the water and catalyst.
At
commercial scale, management expects to be able to produce ethanol at a lower cost than any competitor due to the fact that the CTS 2.0
process is uncomplicated and efficient, and has high value by-products. We believe an additional significant difference between CTS 2.0
and corn ethanol is the wide range of feedstocks that CTS 2.0 can process compared to corn. The CTS feedstocks are not food and have
much lower costs than corn. In addition, while in corn ethanol only the corncobs are used, the CTS 2.0 uses the whole plant or its waste
products. In the case of king grass vs corn, king grass grows so prolifically that processing king grass with the CTS 2.0 could potentially
yield 3000 gallons per acre per year whereas corn only yields 600 gallons per acre per year.
The
Company has proceeded with engineering and development of its technology towards commercialization. The Company built a second generation
prototype in 2018, and a third generation prototype in 2019. The Company completed its 4 th generation CTS 2.0 prototype system
in July 2020, and upgraded it in 2021. The Company is currently testing the 4 th generation CTS 2.0 to optimize various parameters
towards the engineering and scale up of a commercial size reactor. The Company expects to have its 5 th generation CTS prototype,
along with auxiliary equipment, completed by the beginning of 2022. The Company expects that the 5 th generation CTS 2.0 prototype
will have around 10 times the capacity of the 4 th generation system.
18
The
CTS system converts plant-based feedstock into two product streams, cellulose and lignin, each of which can be converted into multiple
products. 1. Cellulose is broken down into sugars and nanocellulose. Nanocellulose has various uses in various industries including the
pharmaceutical industry. Sugar leads to specialty chemicals and biofuels: ethanol & jet fuel. 2. Lignin can be used in ion exchange
resins, specialty chemicals, or to create bioplastics. It can also be burned as a renewable fuel.
Plan
of Operation
The
Company’s strategy is to diversify its product portfolio to include a number of product lines. These potentially include (1) biofuels
– such as ethanol, or converting ethanol into higher biofuels like jet-fuel and the like; (The Company has a license agreement
in place with Vertimass, LLC, on a non-exclusive basis, to use the patented Verimass Process to convert ethanol into jet-fuel, bio-diesel,
bio gasoline and further green chemical components) (2) selling sulfur-free lignin to ion exchange resin producers; (3) making bioplastics
from lignin; (4) making nanocellulose. We believe these, and other markets, could potentially be highly profitable co-products.
Our
goal is to develop our CTS 2.0 technology to a commercial scale and then seek to either enter into a joint venture or acquire existing
corn ethanol plants to install the CTS 2.0 technology. The Company is also looking into converting ethanol to jet fuel. To minimize dilution
to shareholders, we will seek project-based financing to build (or acquire and retrofit) or joint venture with existing ethanol producers
to produce cellulosic ethanol and lignin/bioplastics and other specialty chemicals from our CTS 2.0 system. We believe retrofitting existing
plants with the CTS 2.0 technology may achieve more rapid commercialization than building new plants. After its first plant is profitable,
the Company intends to grow with additional plants in the United States and explore international growth by either licensing the technology
or forming joint ventures with foreign domestic partners to build plants ourselves.
The
Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency, mandates
a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides
monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs)
or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different
D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. (D6
is for corn ethanol). The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.13 per gallon of ethanol. To
profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.
We
believe that our CTS 2.0 process can potentially produce ethanol profitably at the market price, particularly if we include anticipated
potential revenue streams from by-products, and in conjunction with the D3 RIN that we expect to potentially receive for each gallon
of ethanol.
The
Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization.
As of this date, the Company has generated $194,319 in revenue, however it has not generated any revenues from its core business.
Capital
Formation
On
January 5, 2021, the Company closed a financing at 7.5 cents per share having sold 2,143,332 shares and raised $160,750 from the beginning
of the year until January 5 th .
In
January 2021, the company commenced a new offering of shares of its common stock valued at $0.25 per share. Through the date of filing,
the Company has sold 7,160,000 shares for aggregate proceeds of $1,790,000.
From
January 1, 2021, through the date of filing, the Company issued an aggregate of 223,000 shares of its common stock for services valued
at $46,930.
From
January 1, 2021, through the date of filing, the Company issued an aggregate of 1,166,667 warrants for services. Using a Black-Scholes
asset-pricing model, these warrants were valued at $72,090. They have a 6-month term with exercise prices of 15 cents per share.
19
From
January 1, 2021, through the date of filing, the Company issued options to its managers and employees to purchase 20,730,000 shares of
its common stock for a period between five and ten years at the exercise price of 15 to 30 cents per share. Using a Black-Scholes asset-pricing
model, these agreements were valued at $2,600,409. Only 210,000 of these options have vested, with a valuation of $12,658.
From
January 1, 2021, through the date of filing, 350,000 previously issued options were exercised for proceeds of $12,900. In addition, 250,000
options were exercised on a cashless basis for 177,778 shares.
From
January 1, 2021, through the date of filing, warrants were exercised, for the purchase of 13,455,009 shares of common stock, at prices
ranging from $0.005 to $0.25 per share for total proceeds of $1,302,817.
From
January 1, 2021, through the date of filing, $279,000 of debt issued during Chapter 11 was exchange for 7,080,000 shares of stock.
Going
Concern
The
Company has incurred losses since inception, has a working capital deficiency, and may be unable to raise further capital. At June 30,
2021, the Company had a working capital surplus of $1,465,475 and had incurred accumulated losses of $47,781,212 since its inception.
The Company expects to incur significant additional losses in connection with its continued start-up activities. As a result, there is
substantial doubt about the Company’s ability to continue as a going concern based upon recurring operating losses and its need
to obtain additional financing to sustain operations. The Company’s ability to continue as a going concern is dependent upon its
ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient
revenues from its operations to pay its operating expenses.
Results
of Operations
Comparison
of the three and six month period ended June 30, 2021(unaudited) to June 30, 2020
For
the three and six months ended June 30, 2021, the Company recognized $0 in revenue as opposed to $0 in 2020.
For
the three months ended June 30, 2021, the Company’s general and administrative expenses decreased by $384,734 to $293,372 from
$678,106 in 2020. This decrease is primarily the result of a $414,850 decrease in equity-based compensation and a $24,600 increase in
accounting fees, partially offset by an increase in legal fees of $37,902.
For
the six months ended June 30, 2021, the Company’s general and administrative expenses decreased by $278,491 to $599,649 from $878,140
in 2020. This decrease is primarily the result of a $421,281 decrease in equity-based compensation and a $31,900 decrease in accounting
fees, partially offset by an increase in legal fees of $42,942 and an increase in consulting fees of $46,268 related to financings.
Interest
expense decreased in the quarter ended June 30, 2021 by $27,329 to $8,708 from $36,037 in 2020. The decrease in 2021 was primarily the
result of the Company’s decision in 2021 of having paid most of its back pay due, which carries an interest rate of 10% per annum.
Interest
expense decreased in the six months ended June 30, 2021 by $125,785 to $17,457 from $143,242 in 2020. The decrease in 2021 was primarily
the result of the Company’s decision in 2020 to pay interest on back pay due, and in 2021 of having paid most of that back pay
off.
For
the three and six months ended June 30, 2021 the Company recorded non-cash impairments of assets of $33,484, as compared to zero in 2020.
This was the result of disposing of laboratory assets no longer in use.
Research
and development (R&D) costs for the quarter ended June 30, 2021 were $249,786, a decrease of $242,331 from $492,117 in 2020. The
decrease in R&D expenses is primarily the result of a reduction of $414,850 in equity-based compensation offset by an increase in
payroll of $115,950 from the hiring of additional personnel to accelerate the process of commercializing the CTS 2.0 system.
20
Research
and development (R&D) costs for the six months ended June 30, 2021 were $514,860, a decrease of $67,873 from $582,733 in 2020. The
decrease in R&D expenses is primarily the result of a reduction in $414,850 in equity based compensation offset by an increase in
payroll of $220,142.
Liquidity
and Capital Resources
Liquidity
As
of June 30, 2021, the Company had $1,863,097 in cash, and total stockholders’ equity on June 30, 2021, was negative $758,738. As
of December 31, 2020, the Company had $286,579 in cash and total stockholders’ equity at December 31, 2020 was negative $3,336,764.
Total debt, including advances, accounts payable and other notes payable at June 30, 2021, together with interest payable thereon and
contingent liabilities, was $3,293,541 a decrease of $935,725 from December 31, 2020, where it stood at $4,229,266. This decrease is
attributable to the conversion of convertible notes, the forgiveness of the Paycheck Protection Program SBA loan, and the repayment of
the majority of deferred wages. $1,820,630 of the remaining debt was renegotiated to be payable out of future revenue and $917,502 out
of future profits and otherwise does not come due.
During
the six months ended June 30, 2021, the Company’s operating activities decreased by $313,064 to $1,147,809 from $1,460,873. This
decrease can primarily be attributed to a decrease in equity based compensation of $836,131 offset by an increase salaries and bonuses
of $297,811 and an increase in professional fees of $67,843.
During
the six months ended June 30, 2021, the Company’s investing activities used $129,177 in cash. This can be primarily attributed
to capitalizing $14,504 in patent costs and $114,673 used to purchase machinery and equipment. During the six months ended June 30, 2020,
the Company’s investing activities used $135,818. This is primarily due to the purchase of equipment of $134,718.
During
the six months ended June 30, 2021, the Company generated an aggregate of $3,266,467 through its financing activities, which is an increase
of $2,652,757 from $613,710 during the six months ended June 30, 2020. This increase from the prior year can primarily be attributed
to $1,950,750 in the sale of common stock through the Company’s private offerings in 2021, and $1,315,717 in proceeds from the
exercise of warrants and options.
Capital
Resources
At
this time, the Company has limited liquidity and capital resources. To continue funding its operations, the Company will need to generate
revenue or obtain additional financing for current and future operations. The Company anticipates needing around $10 million to optimize
and scale up its CTS 2.0 system to be commercially ready. The Company anticipates reaching this stage around 18 months after financing.
There is no guarantee that we will achieve this additional funding.
As
of the date of filing, the Company has raised $3,266,467 in 2021, through the issuance of common stock and the exercise of warrants and
options, in addition to $10,998,234 through the end of 2020, for a total of $14,254,701, in addition to capital raised through debt or
convertible notes. However, there is no guarantee that the company will be able to raise any additional capital on terms acceptable to
the Company.
The
inability to obtain this funding either in the near term and/or longer term will materially affect the ability of the Company to implement
its business plan of operations and jeopardize the viability of the Company. In that case, the Company may need to reevaluate and revise
its operations.
Equity
As
of June 30, 2021, shareholders’ equity was negative $758,738.
There
were 272,311,065 shares of common stock issued and outstanding as of June 30, 2021.
There
were no preferred shares outstanding.
The
Company has paid no dividends.
21
Critical
Accounting Policies
Off-Balance
Sheet Arrangements
The
Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its
financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or
capital resources that is material to investors.
Seasonality
The
Company’s operating results are not affected by seasonality.
Inflation
The
Company’s business and operating results are not affected in any material way by inflation.
Contractual
Obligations
As
a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As
a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information
required by this Item.
ITEM
4. CONTROLS AND PROCEDURES
Evaluation
of Disclosure Controls and Procedures
We
maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Disclosure controls and procedures
refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the
SEC and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial
officer, as appropriate, to allow timely decisions regarding required disclosure.
As
required by Rule 13a-15(e) of the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision
of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls
and procedures, as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer
and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective as of June 30, 2021
to a reasonable assurance level because of the material weaknesses described below.
Management’s
Annual Report on Internal Controls over Financial Reporting
Management
is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)).
The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally
accepted in the United States of America. Because of its inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls
may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, the
Company conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting as of June 30,
2021 using the criteria established in “Internal Control - Integrated Framework” issued by the Committee of Sponsoring Organizations
of the Treadway Commission (“COSO”).
22
A
material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a
reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented
or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of June 30, 2021,
the Company determined that there were control deficiencies that constituted material weaknesses, as described below.
1.
We
have inadequate cash controls. Although we have separated cash handling and accounting functions, we do not currently require dual
signature on the Company’s bank accounts.
2.
The
Company has insufficient written policies and procedures for accounting and financial reporting with respect to the requirements
and application of US GAAP and SEC disclosure requirements.
3.
Although
the Company retains copies of all financial data and material agreements and backs them up in the cloud, the rest of the Company’s
material agreements may not be. In the event of theft, misplacement, or loss due to fire or other unmitigated factors, it may not
be possible for the Company to retain all of its material financial data and agreements.
Accordingly,
the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual
or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.
As
a result of the material weaknesses described above, management has concluded that the Company did not maintain effective internal control
over financial reporting as of June 30, 2021, based on criteria established in Internal Control—Integrated Framework issued by
COSO.
We
intend to address the material weaknesses discussed above as soon as practicable but we can give no assurance that we will be able to
do so. Designing and implementing an effective disclosure controls and procedures is a continuous effort that requires us to anticipate
and react to changes in our business and the economic and regulatory environments and to devote significant resources to maintain a financial
reporting system that adequately satisfies our reporting obligations. The remedial measures that we have taken and plan to take may not
fully address the material weaknesses that we have identified, and material weaknesses in our disclosure controls and procedures may
be identified in the future. Should we discover such conditions, we intend to remediate them as soon as practicable. We are committed
to taking appropriate steps for remediation, as needed.
All
internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective
can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
Changes
in Internal Control over Financial Reporting
There
has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the
effectiveness of our internal control over financial reporting as of December 31, 2020, that occurred during our fourth fiscal quarter
that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
This
annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control
over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting
firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this annual report.
23
PART
II - OTHER INFORMATION
ITEM
1. LEGAL PROCEEDINGS
The
Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. As of the date of
filing, there are no material claims or suits whose outcomes could have a material effect on the Company’s financial statements.
On
June 21, 2018, Power Up Lending Group Ltd., sued both the Company and four of its managers, ex-managers, and directors of the Company
in the United States District Court for the Eastern District of New York. The case was dropped against the Company and the claim discharged
by the bankruptcy court upon Plan Confirmation on September 18, 2019. Power Up has continued a tort case against the individuals. The
D&O insurance has agreed to cover the CEO Ben Slager, CFO Anthony Santelli, as well as ex-Controller Dennis Lenaburg, in this case.
Management believes the Complaint is frivolous and has filed a motion to dismiss which is pending before the Court as of the date of
this filing.
ITEM
1A. RISK FACTORS.
As
a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information
required by this Item.
ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES
Below
is a list of securities sold by the Company from January 1, 2021, through the date of filing which were not registered under the Securities
Act.
Entity
Date of
Investment
Title of
Security
Amount of Securities
Sold
Consideration
Mark Cox
01/05/21
Common Stock
133,333
Purchased @ $0.075 per share
Dave Vanchina
01/05/21
Common Stock
200,000
Purchased @ $0.075 per share
Pamela McKenna
01/05/21
Common Stock
133,333
Purchased @ $0.075 per share
Michael Bozek
01/05/21
Common Stock
135,000
Purchased @ $0.075 per share
Sean Edmund Burke
01/05/21
Common Stock
133,334
Purchased @ $0.075 per share
Jeffrey Howard
01/05/21
Common Stock
200,000
Purchased @ $0.075 per share
Brian Joseph Burke
01/05/21
Common Stock
275,000
Purchased @ $0.075 per share
Alexander C Shepard
01/05/21
Common Stock
400,000
Purchased @ $0.075 per share
Edmund Burke
01/05/21
Common Stock
266,666
Purchased @ $0.075 per share
Conner Thomas Burke
01/05/21
Common Stock
133,333
Purchased @ $0.075 per share
Kevin Owen Burke
01/05/21
Common Stock
133,333
Purchased @ $0.075 per share
Vestech Securities, Inc.
01/05/21
Common Stock
10,500
Professional Services
Bret Williams
01/05/21
Common Stock
59,500
Professional Services
Tom Camerlengo
01/11/21
Common Stock
200,000
Exercise of Options
Radall Brodsky
01/11/21
Common Stock
333,333
Exercise of Warrants
John Lucken
01/11/21
Common Stock
333,334
Exercise of Warrants
Mary Lucken
01/11/21
Common Stock
166,667
Exercise of Warrants
24
The Loyalty American Companies, Inc.
01/13/21
Common Stock
333,333
Exercise of Warrants
Annie Bindler
01/13/21
Common Stock
50,000
Convertible Debenture
Zachary Bindler
01/13/21
Common Stock
50,000
Convertible Debenture
SLMJ Rocky Opportunity Trust
01/15/21
Common Stock
480,000
Convertible Debenture
Annie Bindler
01/20/21
Common Stock
100,000
Exercise of Warrants
Zachary Bindler
01/20/21
Common Stock
100,000
Exercise of Warrants
John Allen James
01/20/21
Common Stock
200,000
Purchased @ $0.25 per share
Randall Brodsky
01/20/21
Common Stock
80,000
Purchased @ $0.25 per share
John E. Lucken Revocable Trust
01/20/21
Common Stock
80,000
Purchased @ $0.25 per share
Edmund Burke
01/22/21
Common Stock
3,500,000
Convertible Debenture
Edmund Burke
01/22/21
Common Stock
1,000,000
Convertible Debenture
AES Capital Partners
01/22/21
Common Stock
2,000,000
Convertible Debenture
Frank & Joan Costabile Trust
01/25/21
Common Stock
100,000
Purchased @ $0.25 per share
Stacy Costabile
01/25/21
Common Stock
100,000
Purchased @ $0.25 per share
Randall Brodsky
01/26/21
Common Stock
80,000
Purchased @ $0.25 per share
Mary T. Lucken Revocable Trust
01/26/21
Common Stock
80,000
Purchased @ $0.25 per share
John E. Lucken Revocable Trust
01/26/21
Common Stock
80,000
Purchased @ $0.25 per share
Bohdan Rudawski Revocable Trust
01/26/21
Common Stock
100,000
Purchased @ $0.25 per share
Sam Spector
01/26/21
Common Stock
100,000
Purchased @ $0.25 per share
Animated Family Films, Inc
01/26/21
Common Stock
100,000
Purchased @ $0.25 per share
Bruce Greenburg Revocable Trust
01/26/21
Common Stock
250,000
Exercise of Warrants
Chris Kneppers
01/27/21
Common Stock
50,000
Exercise of Warrants
Bill Fitzpatrick
01/27/21
Common Stock
100,000
Professional Services
Audie Rolnick
01/27/21
Common Stock
90,000
Purchased @ $0.25 per share
Makhulu Holdings, LLC
01/29/21
Common Stock
100,000
Purchased @ $0.25 per share
Vecchitto FLP Valori, LLC
01/30/21
Common Stock
900,000
Exercise of Warrants
Annie Bindler
02/01/21
Common Stock
100,000
Exercise of Warrants
Zachary Bindler
02/01/21
Common Stock
100,000
Exercise of Warrants
Adam Langsom
02/01/21
Common Stock
15,000
Exercise of Warrants
Marjorie A Fidler & Michael Fidler
02/01/21
Common Stock
100,000
Purchased @ $0.25 per share
Gregory Nacron
02/01/21
Common Stock
80,000
Purchased @ $0.25 per share
Alexander Dimitrief
02/01/21
Common Stock
75,000
Exercise of Warrants
Arthur Lehrhoff
02/01/21
Common Stock
15,000
Exercise of Warrants
Bernard Lehrhoff
02/01/21
Common Stock
15,000
Exercise of Warrants
Bradley S Schmarak Declaration of Trust
02/01/21
Common Stock
45,000
Exercise of Warrants
Bryan I Schwartz Revocable Trust
02/01/21
Common Stock
15,000
Exercise of Warrants
Daniel J Hyman
02/01/21
Common Stock
15,000
Exercise of Warrants
Daniel Lehrhoff and Patti Lehrhoff Trust
02/01/21
Common Stock
30,000
Exercise of Warrants
David Duckler
02/01/21
Common Stock
30,000
Exercise of Warrants
Diane S Kahan
02/01/21
Common Stock
15,000
Exercise of Warrants
JCH Investments, LLC
02/01/21
Common Stock
75,000
Exercise of Warrants
Kenneth M Berman
02/01/21
Common Stock
15,000
Exercise of Warrants
25
Mason Phelps Revocable Trust
02/01/21
Common Stock
75,000
Exercise of Warrants
Michael Hochman IRA Rollover
02/01/21
Common Stock
21,000
Exercise of Warrants
Randy Abeles
02/01/21
Common Stock
30,000
Exercise of Warrants
Monique Miron
02/03/21
Common Stock
50,000
Purchased @ $0.25 per share
Russel L. Miron
02/03/21
Common Stock
50,000
Purchased @ $0.25 per share
Chris Kneppers
02/05/21
Common Stock
320,000
Exercise of Warrants
Tyler & Brett Properties, LLC
02/05/21
Common Stock
100,000
Purchased @ $0.25 per share
Matthew & Ashley Beck
02/05/21
Common Stock
100,000
Purchased @ $0.25 per share
Capital Consulting, Inc.
02/05/21
Common Stock
100,000
Purchased @ $0.25 per share
Gary Noskin
02/05/21
Common Stock
100,000
Purchased @ $0.25 per share
Martin Schwimmer
02/05/21
Common Stock
100,000
Purchased @ $0.25 per share
Steven C Paul
02/05/21
Common Stock
200,000
Purchased @ $0.25 per share
Vecchio Financial, LLC
02/05/21
Common Stock
200,000
Purchased @ $0.25 per share
PT7, LLC
02/05/21
Common Stock
800,000
Purchased @ $0.25 per share
Julie Kaplan
02/05/21
Common Stock
100,000
Purchased @ $0.25 per share
LK Dayton Investments, LLC
02/05/21
Common Stock
200,000
Purchased @ $0.25 per share
Randall Brodsky
02/05/21
Common Stock
60,000
Purchased @ $0.25 per share
321Gold, Ltd.
02/05/21
Common Stock
200,000
Purchased @ $0.25 per share
Steven Nelson
02/05/21
Common Stock
200,000
Purchased @ $0.25 per share
Jason Walkow
02/05/21
Common Stock
40,000
Purchased @ $0.25 per share
ANIMATED FAMILY FILMS, INC.
02/08/21
Common Stock
100,000
Purchased @ $0.25 per share
Krzysztof Gozdziak
02/08/21
Common Stock
140,000
Purchased @ $0.25 per share
John Piper Jr.
02/09/21
Common Stock
50,000
Purchased @ $0.25 per share
Edward J Piper
02/09/21
Common Stock
50,000
Purchased @ $0.25 per share
M&K Bio LLC
02/09/21
Common Stock
600,000
Purchased @ $0.25 per share
Bradley S Schmarak
02/09/21
Common Stock
100,000
Purchased @ $0.25 per share
Evelyn Varvitsiotes
02/09/21
Common Stock
40,000
Purchased @ $0.25 per share
Paul M Chung Trust
02/09/21
Common Stock
100,000
Purchased @ $0.25 per share
Raymond L Leon
02/10/21
Common Stock
250,000
Purchased @ $0.25 per share
Anthony S De Leo & Paul De Leo JTWROS
02/11/21
Common Stock
200,000
Purchased @ $0.25 per share
Chris Kneppers
02/11/21
Common Stock
130,000
Exercise of Warrants
LABRYS FUND
02/12/21
Common Stock
100,000
Exercise of Warrants
John D Lane
02/12/21
Common Stock
350,000
Exercise of Warrants
John D Lane
02/12/21
Common Stock
362,000
Exercise of Warrants
SLMJ Rocky 2017 Opportunity Trust
02/12/21
Common Stock
1,000,000
Exercise of Warrants
SLMJ Rocky 2017 Opportunity Trust
02/12/21
Common Stock
1,425,000
Exercise of Warrants
SLMJ Rocky 2017 Opportunity Trust
02/12/21
Common Stock
1,815,342
Exercise of Warrants
Tom Camerlengo
02/19/21
Common Stock
150,000
Exercise of Options
Tom Camerlengo
02/19/21
Common Stock
177,778
Cashless Exercise of Options
Chris Kneppers
02/22/21
Common Stock
4,500,000
Exercise of Warrants
Mark Monahan
02/22/21
Common Stock
200,000
Purchased @ $0.25 per share
Jason Taylor
02/24/21
Common Stock
200,000
Purchased @ $0.25 per share
David Gross and Nancy Burgess
02/25/21
Common Stock
200,000
Exercise of Warrants
Vestech Securities, Inc.
03/03/21
Common Stock
6,450
Professional Services
Bret Williams
03/03/21
Common Stock
36,550
Professional Services
Max Assenheimer
03/17/21
Common Stock
10,000
Professional Services
Hazel Holdings, LP
03/22/21
Common Stock
1,000,000
Purchased @ $0.25 per share
Randall Brodsky
04/12/21
Common Stock
60,000
Purchased @ $0.25 per share
Mark Monahan
08/05/21
Common Stock
100,000
Purchased @ $0.25 per share
The
securities issued in the above-mentioned transactions were issued in connection with private placements exempt from the registration
requirements of Section 5 of the Securities Act of 1933, as amended, pursuant to the terms of Section 4(a)(2) of that Act and Rules 504
and 506 of Regulation D.
ITEM
3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM
4. MINE SAFETY DISCLOSURES
Not
applicable.
ITEM
5. OTHER INFORMATION
None.
26
ITEM
6. EXHIBITS
The
exhibits listed below are filed as part of or incorporated by reference in this report.
Exhibit
No.
Identification
of Exhibit
31.1.
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1
Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
27
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
Blue
Biofuels, Inc.
(Registrant)
By
/s/
Benjamin Slager
Benjamin
Slager
Chief
Executive Officer, (Principal Executive Officer)
Date
August
13, 2021
By
/s/
Anthony Santelli
Anthony
Santelli
Chief
Financial Officer (Principal Financial and Accounting Officer)
Date
August
13, 2021
28
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.